Karyopharm Therapeutics
KPTI
119 hedge funds and large institutions have $738M invested in Karyopharm Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
10% more funds holding
Funds holding: 108 → 119 (+11)
0% more capital invested
Capital invested by funds: $737M → $738M (+$992K)
0.51% less ownership
Funds ownership: 72.02% → 71.51% (-0.51%)
8% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 37
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
68% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $3.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.9M |
| 2 |
DM
Deerfield Management
New York
|
+$8.75M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.41M |
| 4 |
BlackRock
New York
|
+$3.78M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$3.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.57M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.85M |
| 5 |
Goldman Sachs
New York
|
-$4.22M |
KPTI Hedge Fund Activity: Q3 2018 in Review
119 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2018, worth a combined $738M — up 0.13% from $737M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KPTI positions and 6 closed out — a net gain of 11 holders — while 34 added to existing stakes and 37 trimmed.
The largest buyer was Candriam SCA, adding an estimated $10.9M. The largest seller was Point72 Asset Management, cutting an estimated $10.9M.
- 119 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2018, up from 108 in Q2 2018.
- Funds reported $738M of Karyopharm Therapeutics stock for Q3 2018, up 0.13% quarter-over-quarter.
- 17 funds opened new Karyopharm Therapeutics positions in Q3 2018 and 6 closed out, a net change of +11 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2018 was Candriam SCA, an estimated $10.9M added.
- The largest Karyopharm Therapeutics seller in Q3 2018 was Point72 Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q3 2018.